Clinical Trials Logo

Clinical Trial Summary

Syncope (fainting) is a common reason for emergency department (ED) presentation. Fainting can be caused by heart conditions such as irregular heart rhythm (arrhythmia) that can be life-threatening, structural heart problems, or serious conditions not related to the heart. The standard or usual treatment for the majority of patients at-risk for irregular heart rhythm is getting discharged home with no heart rhythm monitoring. If patients receive any monitoring, only Holter monitoring device that records all heart beats for 24 hours to 72 hours will be used. One-third to half of irregular heart rhythm will be identified only after patients are either discharged from the ED or hospitalized in an inpatient unit. One-third to half of irregular heart rhythm will be identified only after patients are either discharged from the ED or hospitalized in an inpatient unit. The study hypothesize that prolonged live cardiac rhythm monitoring (15 days) of at-risk syncope patients, discharged from the ED, will lead to identification of irregular heart rhythm, which can lead to improved patient safety and lower healthcare costs.

Clinical Trial Description

Syncope is defined as a sudden, transient loss of consciousness followed by spontaneous complete recovery.14 It is caused by transient global cerebral hypoperfusion due to decreased cardiac output, excessive vasodilatation, or both. The most common causes include a)reflex (i.e., vasovagal syncope); b)cardiac syncope; and c)orthostatic hypotension. Syncope accounts for 1-3% of ED visits and ~6% of admissions from the ED to hospital. Each year, syncope accounts for approximately 160,000 ED visits in Canada, with direct hospital costs of approximately $130 million. ED management of syncope: Overall, up to 10% of patients seen in the ED for syncope will have serious underlying conditions e.g., serious arrhythmia, myocardial infarction, significant hemorrhage, pulmonary embolism] identified and/or die from these conditions within the next 30 days. Until recently, valid and reliable evidence to inform these decisions has been lacking. Professional medical societies in Europe and North America have long called for the development of practical and accurate tools to stratify patients into low, intermediate, and high-risk groups to aid in management decisions. One-third to half of these serious conditions will be identified ONLY AFTER they are either discharged from the ED or hospitalized in an inpatient unit, emphasizing the challenge in risk-stratification and ED disposition decision-making. Of these serious conditions that are identified after ED disposition, 68.8% are arrhythmias. While the non-arrhythmias are identified in the first few days after the ED visit , arrhythmias tend to be identified up to two weeks after the ED visit. The hypothesis is that prolonged live cardiac rhythm monitoring of at-risk ED syncope patients, defined as those with CSRS score ≥3 discharged from the ED, will lead to identification of important arrhythmia or ruling out an arrhythmic etiology and consequently to improved patient safety and lower healthcare costs. Preliminary work: Two large multicentre prospective studies were completed to derive and validate the Canadian Syncope Risk Score (CSRS) by enrolling 8176 patients from 11 Canadian EDs in whom no serious condition was identified during the index ED evaluation. The CSRS was developed conforming to both methodological standards for clinical decision tool development and reported as per the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) guideline. Overall, 9.0% of patients were hospitalized and 3.6% suffered 30-day serious outcomes after ED disposition. The CSRS score ranges from -3 to +11. The risk categories were simplified into low, medium, and high, and the 30-day serious outcomes for each of the three risk categories. The incidence of arrhythmias in the medium and high-risk groups were 4.9% and 18.0% respectively. Given the importance of occult arrhythmia and uncertainty regarding the optimal duration of cardiac monitoring, the time interval was analyzed from ED arrival to arrhythmias detection/intervention or unexplained death and found that half of all arrhythmic outcomes were identified within 2 hours among low-risk patients and within 6 hours among medium- and high-risk patients. Furthermore, the more serious, ventricular arrhythmias occurred only in medium and high-risk patients, and 92% of all arrhythmias among these risk groups were identified within 15 days. These latencies are highly relevant to decisions regarding the utility of cardiac monitoring during and after an ED visit for syncope, with implications for the rational deployment of emerging technology such as outpatient telemetry which permits real-time identification of serious arrhythmias. The above inferences regarding cardiac rhythm monitoring are based on the secondary analysis of observational data. There are no previous randomized controlled trials (RCTs) that assess the role of outpatient prolonged cardiac monitoring to detect occult arrhythmias among CSRS medium and high-risk syncope patients discharged from the ED. There is a wide variations in ED management, including admission rates (range from 5.3% to 19.6% among sites) and outpatient cardiac testing, very low yield for advanced neuroimaging, and inefficiencies in hospital admission (among those hospitalized, 46.5% were for suspected arrhythmias, of whom 71.2% had no cause for syncope identified during hospitalization. Analyzing our cohort, the study found that CSRS low-risk patients will benefit the least from hospitalization and CSRS high risk patients the most. Currently, 21.6% of CSRS medium-risk patients are hospitalized primarily because of concern for underlying arrhythmia, yet the mortality and the likelihood of identifying an underlying ventricular arrhythmia within 30 days among these patients is very low. Advances in ambulatory cardiac rhythm monitoring suggest that this group is an ideal target for outpatient monitoring, forgoing hospital. admission after ED assessment. A pilot study was recently with 15-day out of hospital live cardiac rhythm monitoring of 72 CSRS medium and high-risk patients and found that live cardiac monitoring of at-risk ED syncope patients is feasible, safe, and acceptable. Hypothesis: the study hypothesize that a strategy of prolonged outpatient cardiac rhythm monitoring compared to usual care of at-risk syncope patients, defined as those with CSRS score ≥3 when discharged from the ED will lead to improved detection of arrhythmias that require treatment and improve patient safety, healthcare efficiency and patient satisfaction. What are the principal research questions to be addressed? The overall objective of this study is to evaluate a strategy of 15-day live cardiac rhythm monitoring versus usual care at improving the identification of an arrhythmia that required treatment among at-risk syncope patients discharged from the ED through a patient level RCT. The overall objective of this study is to evaluate a strategy of 15-day live cardiac rhythm monitoring versus usual care at improving the identification of an arrhythmia that required treatment among at-risk syncope patients discharged from the ED through a patient level RCT. Trial Design: prospective patient-level multi-center RCT involving 13 participating EDs across Canada. During the trial period, syncope patients will be block randomized to usual care or prolonged outpatient cardiac rhythm monitoring in blocks of variable sizes and stratified by risk scores (3-5, ≥6) and study site. Patients randomized to usual care will receive all care as prescribed by the discharging physician and there will be no study specific interventions. Patients randomized to the intervention arm will receive 24/7 live cardiac rhythm monitoring for 15 days (cardiophone; an external loop recorder). If a patient is randomized to the intervention arm and was prescribed outpatient cardiac monitoring such as Holter monitor, this will be replaced by the 24/7 live monitoring and will be applied either prior or within 24 hours of discharge from the ED. As the intervention arm provides 24/7 live cardiac monitoring which is a higher level of care than the control arm, there is no safety risk to the patients in the intervention arm. Cardiophone evaluates all cardiac beats and rhythm abnormalities that are detected as per the algorithm programmed into the device. These abnormalities are then automatically and immediately transmitted to a central monitoring station without the need of any patient intervention (device-triggered transmission). Additionally, the cardiac rhythm can also be transmitted to the monitoring station immediately in the event the patient experiences symptoms, by the touch of a button on the device (patient-triggered transmission). The central monitoring station is in Windsor, Ontario (Canadian Cardiac Care) and is staffed round the clock by certified electrocardiographic technicians and a cardiologist on-call. Timeline and follow up: the study timeline is 18 months of patient enrollment and data collection. The duration of treatment period for patients in the intervention arm will receive 15 days of cardiac monitoring. All study patients will be followed at 30 days either by telephone or email and at 1-year through data linkage with provincial health database. Embedded observational study: validation of the CSRS ultra-low-risk criteria and to evaluate if the CSRS can be updated to improve its accuracy, ED physician to obtain verbal consent from patients who are lower risk (score <3) for 30-day follow-up and addition of cardiac biomarker using the left-over blood at study centers that are able to accomplish such additional testing for research purposes. These patients will not be enrolled in the randomized controlled trial. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05066347
Study type Interventional
Source Ottawa Hospital Research Institute
Contact Bahareh Ghaedi, MSc, CCRA
Phone 613-823-1299
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date November 1, 2021
Completion date June 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT00069693 - Evaluation of Chronic Orthostatic Intolerance N/A
Completed NCT02565238 - BIO.MASTER.BioMonitor 2 Study N/A
Active, not recruiting NCT01965899 - Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System N/A
Completed NCT00746564 - Study of New Implantable Loop Recorder N/A
Completed NCT00359203 - ISSUE3: International Study on Syncope of Uncertain Etiology 3 Phase 4
Recruiting NCT04198220 - BIO|STREAM.ICM Obesity
Recruiting NCT04533425 - Practical Approaches to Care in Emergency Syncope
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Recruiting NCT03786640 - Abbott Brady 3T MRI PMCF
Recruiting NCT03803969 - ConfirmRxTM: Posture and Activity N/A
Recruiting NCT04075084 - Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)
Active, not recruiting NCT02786940 - Remote Cardiac Monitoring of Higher-Risk Emergency Department Syncope Patients After Discharge - A Pilot Study N/A
Completed NCT02952781 - Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial N/A
Completed NCT02324920 - Benefit of Dual-chamber Pacing With Closed Loop Stimulation (CLS) in Tilt-induced Cardioinhibitory Reflex Syncope N/A
Completed NCT02316860 - The Diagnostic Performance of Tilt Test in Athletes N/A
Completed NCT02457455 - Urgent Medical and Surgical Conditions During Flights N/A
Completed NCT00093860 - Propranolol to Treat Fainting in Children With Sympathoadrenal Imbalance Phase 2
Completed NCT00279279 - PREPARE - Primary Prevention Parameters Evaluation N/A
Active, not recruiting NCT04025710 - Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep) N/A
Completed NCT00096902 - Non-Pharmacologic Therapy for Neurocardiogenic Syncope Phase 2